Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Steroids. 2018 Apr 26;135:36–49. doi: 10.1016/j.steroids.2018.04.009

Figure 3.

Figure 3

Comparison and grouping of rexinoids via gene expression analysis. Figure 3a. Group 1 analogs versus bexarotene. Group 1 analogs contain those compounds which expressed the most substantial changes from bexarotene. Members of this group have at least 4 study genes with greater than |1.8| fold changes from bexarotene the number of study genes which sort into one of 3 tranches representing increasing magnitudes of fold-changes from bexarotene. Green bars represent the number of genes with a greater than 1.2 but less than 1.8 fold change (absolute) as compared to bexarotene. Yellow bars represent the number of genes with a greater than 1.8 but less than 2.4 fold change (absolute) as compared to bexarotene. Red bars represent the number of genes with a greater than 2.4 fold change (absolute) as compared to bexarotene. Figure 3b. Group 2 analogs versus bexarotene. Group 2 analogs contain those compounds which expressed intermediate changes compared from bexarotene as compared to groups 1 or 3. Members of this group have either least one study genes with a greater than |1.8| fold change from bexarotene, or five or more total changes from bexarotene of a magnitude greater than |1.2| fold. Green bars represent the number of genes with a greater than 1.2 but less than 1.8 fold change (absolute) as compared to bexarotene. Yellow bars represent the number of genes with a greater than 1.8 but less than 2.4 fold change (absolute) as compared to bexarotene. Red bars represent the number of genes with a greater than 2.4 fold change (absolute) as compared to bexarotene. Figure 3c. Group 3 analogs versus bexarotene. Group 3 analogs contain those compounds which expressed the fewest substantial changes from bexarotene. Members of this group have four or fewer |1.8| magnitude fold change differences from bexarotene. Green bars represent the number of genes with a greater than 1.2 but less than 1.8 fold change (absolute) as compared to bexarotene.